ClinicalTrials.gg
TerminatedNCT05839509Updated Feb 18, 2025

Phase 2 Clinical Trial of GH001 in Bipolar II Disorder

A Phase 2 interventional study of GH001 in Bipolar II Disorder, sponsored by GH Research Ireland Limited. Terminated at 7 sites in 3 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by GH Research Ireland Limited · Phase 2, Interventional, and Treatment

Why this study was terminated
Recruitment of this patient population was more challenging than anticipated. The sponsor concluded that a sufficient amount of patients have completed the trial to demonstrate proof of concept in this patient population.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Bipolar Disorder with a site in Germany — 6 open to participants now, 7 under way, 2 of them phase 3. Bipolar Disorder · Germany.

Enrollment
35th of 36
6 · median 174
Started
2023
the only one that year
Phase 2
2 of 41
none open now
Registered
36th of 41
by date

Among the 41 studies in Bipolar Disorder with a site in Germany, this one is the 35th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 2, and was the 36th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

6 of the 41 studies in Bipolar Disorder with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Bipolar Disorder with a site in Germany, or all of them as a file.
02

Study summary

This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 participants with clinically diagnosed bipolar disorder (BD) type II and experiencing a current episode of depression will be included in this study. The participants will receive an individualized dosing regimen (IDR) with at least one and up to three doses of GH001 administered within a single day.

03

Conditions studied

  • Bipolar II Disorder

Keywords

  • Depression
  • Bipolar Disorder
  • 5-Methoxy-N,N-Dimethyltryptamine
  • 5-MeO-DMT
  • Mebufotenin
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is male or female and in the age range between 18 and 64 years (inclusive) at screening
  • Has a (BMI) in the range of 18.5 and 35 kg/m2 (inclusive) at screening
  • Meets the trial criteria for bipolar II disorder and is experiencing a major depressive episode, as assessed by a trial psychiatrist or registered clinical psychologist

Exclusion criteria

Exclusion Criteria:

  • Has bipolar II disorder with rapid cycling (four or more episodes of hypomania or depressive episodes in previous 12-month period)
  • Has, based on history, psychiatric assessment, and evaluation of the MINI, a current or prior diagnosis of bipolar I disorder, a manic episode, a psychotic disorder, MDD or other mood disorder with psychotic features, obsessive compulsive disorder, PTSD, autism spectrum disorder, borderline personality disorder, schizophrenia, delusional disorder, paranoid personality disorder, schizoaffective disorder, intellectual disability, or any other psychiatric comorbidity that renders the patient unsuitable for the trial according to the investigator's judgment
  • Has one or more first degree relatives with a current or previously diagnosed psychotic disorder, bipolar I disorder or MDD with psychotic features
  • Has taken prohibited medication or prohibited dietary supplements within the specified timeframe prior to dosing
  • Has previously experienced a significant adverse reaction to a hallucinogenic or psychedelic drug according to the investigator's judgment
  • Has a clinically significant abnormality in physical examination, vital signs, , or clinical laboratory parameters which renders the patient unsuitable for the trial according to the investigator's judgment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    GH001 Individualized Dosing Regimen

    GH001 (Mebufotenin, 5-Methoxy-N,N-Dimethyltryptamine) is administered via inhalation, as an IDR consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience \[PE\]) at the previously administered dose.

    Drug: GH001

Interventions

  • DrugGH001

    GH001 administered via inhalation

    Also known as: 5-Methoxy-N,N-Dimethyltryptamine, 5-MeO-DMT, Mebufotenin

06

What researchers measure

Primary outcomes

  1. The anti-depressive effects of GH001 evaluated by the change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) assessed at Day 7

    The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item is scored from 0 to 6. The overall score ranges from 0 to 60.

    Time frame: From Baseline to Day 7

07

Study locations

7 sites
  • Investigational Site
    Dresden, Germany
  • Investigational Site
    Frankfurt, Germany
  • Investigational Site
    Münster, Germany
  • Investigational Site
    Leiden, Netherlands
  • Investigational Site
    Maastricht, Netherlands
  • Investigational Site
    London, United Kingdom
  • Investigation Site
    Oxford, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Nov 2024, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2023
First posted
May 3, 2023
StartActual
Apr 6, 2023
Primary completionActual
Nov 13, 2024
CompletionActual
Dec 5, 2024
Last update
Feb 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05839509
Lead sponsor
GH Research Ireland Limited
Responsible party
Sponsor
First posted
May 3, 2023
Start date
Apr 6, 2023
Primary completion
Nov 13, 2024
Completion
Dec 5, 2024
Last update
Feb 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxydimethyltryptamines

Start the discussion